PLUS THERAPEUTICS INC (PSTV)

Company Profile

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The company is headquartered in Austin, Texas and currently employs 17 full-time employees. The company went IPO on 2000-08-09. The firm is focused on developing treatments for patients battling cancer. The firm develops a targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. Its lead radiotherapeutic candidate, Rhenium (186Re) obisbemeda is designed specifically to CNS cancers including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. The Company’s portfolio also includes 188RNL-BAM, a radioembolization therapy for liver cancer.

Company Info

PLUS THERAPEUTICS INC

4200 Marathon Blvd Ste 200

Austin TEXAS 78756

P: 17372557194

CEO: Marc. H. Hedrick

Employees: 17

Website: http://www.plustherapeutics.com/